Moxonitex tabs 0.4mg #28

Moxonitex user manual

To buy Moxonitex tablets just add it to your shopping cart

Composition

In one film-coated tablet, there may be 0.2 mg / 0.3 mg / 0.4 mg of moxonidine.
Auxiliary inactive substances are 94.4 mg lactose monohydrate, 2 mg povidone K25 and 3 mg crospovidone, and 0.3 mg magnesium stearate.
The film shell of Opadry Y 1 7000 (weight 3.465 mg) includes: 1.083 mg of titanium dioxide, 2.165 mg of hypromellose, 0.217 mg of macrogol 400, and also a dye-iron red oxide - 0.035 mg.

Form of issue

Moxonitex is manufactured in tablets, packaged in blisters of 7, 10, 14 tablets, sealed in cardboard packs containing from 1 to 2, 3, 4, 5 blisters.

pharmachologic effect

This drug has antihypertensive effect.

Pharmacodynamics and pharmacokinetics

Moxonitex is a selective agonist of imidazoline receptors. He is responsible for reflex regulation of the sympathetic nervous system and receptors located in the ventrolateral zone in the oblong brain. Significantly binding to central α2-adrenergic receptors is capable of reducing diastolic and systolic blood pressure both as a result of single dose administration and prolonged therapy (duration of effect is more than 12 hours). In addition, long-term treatment results in:
    to a decrease in left ventricular hypertrophy, leveling the symptoms of myocardial fibrosis with microarteriopathy, normalizing the capillary blood supply to the heart muscle, reducing the overall peripheral (OPSS) and pulmonary vascular resistance without significantly changing the volume of cardiac output and heart rate;
    to a decrease in the activity of epinephrine and norepinephrine, as well as renin, angiotensin II, aldosterone in the blood plasma, with physical loads - PNP (atrial natriuretic peptide);
    to a decrease in tissue resistance to insulin by 21% relative to patients taking placebo, obese patients, moderate arterial hypertension, and insulin resistance;
    to stimulate the release of growth hormones, which has no effect on the metabolism of glucose or lipids.

Data on pharmacokinetics

As a result of oral absorption, the absorption is approximately 90% regardless of nutrition. A single dose has a bioavailability of up to 88% and reaches a maximum concentration in the bloodstream of 1-3 ng / ml after 0.5-3 hours. Time from the maximum level to a pronounced decrease in blood pressure at rest is usually different by 10%, and at a load - by 7.7%. Moxonidine binds to blood plasma proteins by 7%, is able to penetrate the BBB, does not accumulate in the tissues.
It is excreted by 90% kidneys, where 50-75% is unchanged substance, and 20% - metabolites. Half-life is 2-3 hours.

Indications for use

Indications for use Moxonitex is arterial hypertension.

Contraindications

Moxonitex tablets should not be prescribed:
    with syndrome of weakness of the sinus node or sinoatrial block;
    with AV blockade of the 2nd and 3rd degree;
    with chronic heart failure III-IV class (NYHA);
    with unstable angina;
    with severe hepatic insufficiency;
    the existing galactose intolerance, the established deficiency of the lactase enzyme, the glucose-galactose insufficiency insufficiency syndrome (malabsorption);
    if there is an angioedema in the anamnesis;
    with a pronounced bradycardia - up to 50 beats per minute at rest;
    at the expressed infringements of a warm rhythm;
    with renal insufficiency of severe degree (CC less than 30 ml / min, serum creatinine content - more than 160 μmol / l);
    age group: minors (under 18 years);
    the period of breastfeeding;
    hypersensitivity to the components of Moxonitex tablets.
It is necessary to monitor the doctor and prescribe with caution
    in the case of a recent myocardial infarction;
    for violations of peripheral circulation, for example, Raynaud's syndrome or intermittent claudication;
    patients with mild functional impairment of the kidneys (KK within 30-60 ml per 1 minute, and serum creatinine - 105-160 micro moles per 1 liter);
    patients with functional disorders of the liver;
    pregnant women;
    patients in a depressed state;
    with glaucoma, Parkinson's disease or epilepsy.

Side effects

Determination of the incidence of side effects for the bottom product has the following gradation: frequent cases, if it exceeds 1%, rare - from 0.01 to 0.1%, sometimes - less than 0.01%.
    CNS: cases of dizziness, headaches, drowsiness, increased fatigue, sleep disturbances are frequent, "paresthesia, depression and increased anxiety were sometimes" registered.
    Sense organs: sometimes cases of dry eyes have been reported.
    CCC: rare cases - manifestations of vasodilation; sometimes a marked decrease in blood pressure (BP), syncope, Raynaud's syndrome or peripheral edema was recorded.
    Digestive system: cases of dry mouth, nausea, anorexia, constipation are frequent.
    Genitourinary system: sometimes there was a delay or incontinence, cases of impotence and decreased libido.
    The immune system: urticaria, itching, exanthema, until the development of angioedema.
    Among others: sometimes there was gynecomastia and pain in the parotid glands.

Moxonitex, instructions for use (Method and dosage)

Tablets should be taken orally, with plenty of water.

Standard dosage

The recommended initial dose: 0.2 mg (in the morning). In case of insufficient therapeutic effect, it is recommended to increase the dose (after 3 weeks) to 0.4 mg per day for 1 or 2 doses. It should be taken into account that the maximum daily dose should not exceed 0.6 mg, and the maximum single dose should be 0.4 mg.
With moderately expressed functional lesions of the kidneys
Implies the clearance of creatinine from 30 to 60 ml per 1 min. The recommended single dose should not exceed 0.2 mg, with a maximum daily dose - up to 0.4 mg.
Attention!
Cancellation of the drug Moxonitex should occur gradually, and if it is necessary to stop taking concomitantly with the received β-adrenoblockers, then β-adrenoblockers are first abolished, and then after a few days - Moxonitex.

Overdose

It is accompanied by the following symptoms:
headache, marked decrease in blood pressure, bradycardia, palpitations, weakness, drowsiness, dryness of the oral mucosa. In rare cases, vomiting and epigastric pain have been reported, hypertension and paradoxical hypertension are potentially considered.

Method of treatment

Symptomatic therapy (since no specific antidote is found):
    marked decrease in blood pressure - it is recommended to restore the volume of circulating blood (BCC) by introducing a liquid;
    α-adrenergic receptor antagonists are used to reduce or completely eliminate hypertension.

Interaction

Against the background of the use of various drugs with Moxonidine, the following reactions may occur:
    With other antihypertensive drugs - mutual enhancement of effects.
    With β-adrenoblockers - increased bradycardia, severity of negative dromotropic, as well as inotropic action.
    There is an increase in the hypotensive effect with ethanol, sedatives, blockers of slow Ca channels, incl. derivatives of dihydropyridine.
    Tolazolin dose-dependent decreases in hypotensive effect.
    It is not recommended to take Moxonitex with tricyclic antidepressants.

Terms of sale

You don't need a prescription to buy Moxonitex.

Storage conditions

Requires a temperature regime: up to + 25 ° Celsius.
Keep in a place inaccessible to minors.
Shelf life - 24 months.

special instructions

Moxonidine therapy means regular monitoring of such parameters as blood pressure and heart rate, as well as ECG.

In pregnancy and lactation

The use during pregnancy is possible only if: the supposedly greater benefit of the therapeutic effect for the mother compared with the possible risk to the fetus.

Moxonitex Reviews

Reviews about the drug are few. Doctors point out the effectiveness of the drug at a fairly low price.
Patients taking Moxonitex complain of dizziness, headache and uncontrolled excessive BP reduction.